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Huntington’s disease is an autosomal dominant progressive neurodegenerative disease, which results in a decreased quality of life 
and an early death. A high prevalence of vitamin D deficiency was first described in a 2013 study in patients with manifest Huntington’s 
disease, where serum vitamin D level was found to be associated with motor capabilities of the patients. Objectives: Our objective was 
to investigate the effect of a high-dose vitamin D3 supplementation on a transgenic mouse model of Huntington’s disease. Methods: Our 
study was performed on N171-82Q Huntington’s disease transgenic mice in age- and gender-matched groups. We collected data on the 
motor state and survival of the mice. Results: The results demonstrate that though vitamin D3 had no effect on the motor performance 
of transgenic mice, but significantly increased the lifespan of transgenic animals (Kaplan-Meier survival curves: vehicle-supplemented 
group: 73 (67–94) days vs. vitamin D3-supplemented group: 101 (74–109) days, p=0.048 Mantel-Cox log rank test). Conclusions: Further 
investigations are needed to determine whether a neuroprotective or a general corroborative effect of vitamin D leads to the measured 
effect. Our findings support the potential influence of vitamin D deficiency on the disease course and propose that vitamin D may be an 
effective supplementary treatment to beneficially influence clinical features of Huntington’s disease.
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INTRODUCTION
Huntington’s disease (HD) is an autosomal dominantly 
inherited, progressive neurodegenerative disease, with its 
initial symptoms presenting mainly during early adulthood. 
Involuntary choreiform motor symptoms are typical 
presentations of the disease, accompanied by cognitive 
and psychiatric symptoms. The primary symptoms are 
attributable to neuronal dysfunction and death evoked 
by mutant huntingtin protein (mHtt). The most affected 
brain region which is responsible for the characteristic 
movement disorder is the striatum, in particular the 
medium-sized GABAergic spiny neurons. Disturbances in 
transcription, translation, protein folding (Trześniewska 
et al. 2004), energy metabolism, antioxidant defense, and 
the maintenance of cellular homeostasis cause impaired 
neuronal function and finally lead to cell death (Szalardy et 
al. 2012). Although, the underlying genetic cause and some 
aspects of the progression are well-known, an effective 
treatment for HD is still pending (Frank and Jankovic 
2010). Symptomatic medications are available for the 
management of various motor and psychiatric symptoms. 
Today, decades after the introduction of animal models 
for HD, a huge database of preclinical studies is available. 
During this time, numerous drugs have been reported to be 
beneficial in rodents; however, only tetrabenazine has been 
concluded to demonstrate consistently positive outcome, 
though only on chorea (Killoran and Biglan 2014).
In the past years, 1,25-dihydroxyvitamin D3 (VD3) has 
been shown to be present in the blood in a diminished 
level in certain neurodegenerative diseases, including 
Alzheimer’s dementia (AD) (Littlejohns et al. 2014) and 
Parkinson’s disease (PD) (Mehanna et al. 2014), often 
describing decreased bone mass as well in these patients. In 
addition, the development of these diseases have also been 
associated with polymorphisms and certain haplotypes of 
vitamin D receptor (VDR) (Łaczmański et al. 2015, Torok 
et al. 2013). Furthermore, a negative correlation between 
serum VD3 levels and disease severity has repeatedly been 
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VD3-deficiency might contribute to the neurodegenerative 
process in these diseases. Corresponding with findings in 
AD and PD, a decrease in bone density was described in 
patients with premanifest HD, suggestive of VD3 deficiency 
(Goodman and Barker 2011). More recently, a notably 
reduced serum level of VD3 has been reported in advanced 
HD as a first direct evidence of VD3 deficiency in the disease, 
with serum VD3 levels found to be in positive association 
with motor capabilities of the patients with HD (Chel et al. 
2013). These findings altogether suggest the contribution 
of VD3 deficiency/insufficiency in the pathogenesis and/or 
severity of these neurodegenerative diseases, and propose 
a potential neuroprotective role of VD3 supplementation. 
VD3 is discussed to exert neuroprotective effects via VDR, 
with a number of different mechanisms of action implicated. 
These proposed mechanisms include the elevation of 
the antioxidant glutathione levels in neural cells by the 
upregulation of expression of γ-glutamyl transpeptidase in 
astroglia (Garcion et al. 1998, 2002); the attenuation of nitric 
oxide synthesis via the downregulation of inducible nitric 
oxide synthase (iNOS) (Durzun et al. 2013, Chen et al. 2000, 
Ciesielska et al. 2003); the upregulation of genes involved 
in processes counteracting neuroinflammation (Nissou et 
al. 2014), a feature also characteristic of neurodegenerative 
disorders; the initiation of histone acetylation and 
demethylation (Fetahu et al. 2014, Pickholtz et al. 2014), 
epigenetic modifications widely linked to neuroprotective 
actions (Ziemka-Nalecz and Zalewska 2014, Zadori et al. 
2009, Gardian et al. 2004); as well as the upregulation of 
neurotrophic factors (Garcion et al. 2002). 
These mechanisms of VD3 may protract the development 
of symptoms and may take positive effect on the lifespan 
of patients with neurodegenerative disease, including 
HD. In line with these proposed protective effects, an 
increasing number of preclinical evidence suggest the 
neuroprotective effects of VD3 supplementation in rodent 
models of AD (Durk et al. 2014) and PD (Kim et al. 2006, 
Wang et al. 2001), and promising clinical trials have also 
been published (Chaves et al. 2014). However, there is a 
paucity of experimental data on the potential therapeutic 
effect of VD3 in HD. Based on the positive results of studies 
with VD3 in models of other neurodegenerative diseases, we 
report the first study assessing the therapeutic potential of 
VD3 in an animal model of HD.
METHODS
Experimental animals and drug administration
In our experiment, we used N171-82Q, also known as 
B6C3-Tg(HD82Gln)81Gschi/J HD transgenic mice. This 
transgenic strain is characterized by a selective neuronal 
expression of an N-terminal fragment of mutant huntingtin 
gene containing exon 1 and 2, including a 82 amino 
acid-long polyglutamine region. These mice develop 
a movement disorder, including tremor and hypokinesis, 
together with intranuclear inclusions, neuritic aggregates, 
and striatal atrophy at the morphological level (Schilling et 
al. 1999, Zadori et al. 2011). The decreased life expectancy 
makes this strain a suitable animal model of the disease. 
N171-82Q transgenic HD (n=24) and wild-type (WT) (mixed 
background containing C57BL/6J and C3H/HeJ, referred 
to as B6C3F1) (n=16) mice were examined longitudinally 
from 7th to 16th weeks of age. Groups were matched in age 
and gender.
The animals were housed in cages under standard 
conditions with a 12–12-h light–dark cycle and free 
access to food and water. The experiment was carried out 
in accordance with the European Communities Council 
Directive (86/609/EEC) and was approved by the local 
animal care committee.
Animals of N171-82Q and WT strains were divided 
into control (WT-vehicle and HD-vehicle) and VD3-
-supplemented (WT-VD3 and HD-VD3) groups (12-12 in the 
transgenic and 8-8 in the WT group). VD3-supplemented 
mice subcutaneously received cholecalciferol (Vigantol® 
50000, Merck KgaA, Darmstadt, Germany) in a dose of 
12000 IU/kg (emulsification: 0.5 g Tween 80+8975 μl 
0.1 M phosphate-buffered saline (PBS)+1025 μl Vigantol). 
Mice in the control groups received vehicle (0.5 g Tween 
80+10000 μl 0.1 M PBS). Animals were injected 5 times 
a week after behavioral tests with an average of 120 µl of 
the emulsion.
Experimental design
Experimental animals were first measured for the native 
(treatment-free) parameters of their motor capabilities in 
the rotarod test and open-field test in their age of 7th weeks 
to rule out inherited differences between the randomly 
generated groups. Treatment was started in the 8th week of 
age of the animals. Motor status of the mice was monitored 
with rotarod test on a weekly basis, and with open-field test 
in every second week of the study. Behavior assessments 
were performed till there was a minimum satisfactory 
sample size of 5 per group. The treatment was continued 
until the death of the last mouse from the N171-82Q strain.
Behavior testing
Open-field test
Spontaneous locomotor and exploratory activity was 
investigated with a computer-assisted open-field apparatus 
(Conducta v2.0, Experimetria Ltd., Budapest, Hungary). 
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Mice were put into the measure box for 15-min tracking 
sessions. We used a light intensity of a standard 2 lux for 
the tracking sessions, measured inside the apparatus. 
Motimetry tests were repeated on every 14th day.
Rotarod tests
Motor coordination ability of the animals was examined 
on a computer-assisted rotarod apparatus (TSE RotaRod 
Advanced, TSE Systems GmbH, Bad Homburg, Germany) 
on every 7th day. The apparatus is supplied with rods of 
30 mm in diameter. Mice were trained on the rotarod for 
2 days before the first examination day. Each training day 
consisted of 3 sessions of a 5-min train. Rotation speeds 
of 5 rpm (rotation per minute) and 10 rpm were applied 
on training day #1 and #2, respectively. The examination 
was performed with an accelerating speed profile 
gradually increasing from 1 rpm to 30 rpm during the 
5-min period. Each animal was examined 3 times on the 
days of examination with a 30 min resting interval. The 
latency to fall values were registered and their averages 
were used for subsequent analysis. Repeated examinations 
on the subsequent weeks were carried out with the same 
accelerating speed profile as detailed before. On the days 
preceding each examination day, reminder trainings were 
applied, consisting of two 5-min sessions with a speed set 
to a constant 10 rpm.
Collection of data of survival
The mice were euthanized (using Forane, 5%) when 
severe hypokinetic state was established. Animals were 
considered to attain this state when they did not manifest 
motor reaction when towed by their tails.
Statistical analysis
Datasets showing Gaussian distribution (tested 
with Shapiro-Wilk test) were compared with one-way 
ANOVA. For the assessment of between-group difference, 
parametric (Bonferroni post hoc test) or non-parametric 
(Mann-Whitney U test) tests were applied according to 
the distributions of the datasets. (Variances were equal in 
all cases, as tested with Levene’s test.) Analysis of survival 
was performed with Mantel-Cox test for the comparison of 
Kaplan-Meier survival curves. Data are presented in mean 
±standard deviation and median (interquartile range) in 
case of normally and non-normally distributed parameters, 




The pre-treatment native analysis of ambulatory 
parameters revealed no significant differences between 
the a priori randomized groups in any of the examined 
parameters, enabling valid further investigations (data not 
shown). The waning capability for spontaneous locomotion 
in the N171-82Q strain was detectable as early as week 11 for 
both the distance travelled (WT-vehicle: 3721.9±849.8 cm 
vs. HD-vehicle: 2099.8±1249.3 cm, p=0.025 Bonferroni post 
Fig. 1. Representative image of the A total distance ambulated in the open-field and the total number of the rears B at week 13. A significant decrease in 
the ambulated distance was shown in vehicle-treated HD mice. A robust difference was measured in the number of the rears among WT and HD mice 
treated with vehicle. HD mice treated with VD3 did not show alteration in ambulated distance or in the number of rears compared to vehicle-treated HD 
group. VD3 treatment had no adverse effect observable in WT mice.
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hoc test) and the number of rears (WT-vehicle: 103.2±31.1 
vs. HD-vehicle: 27.0±25.1, p<0.001 Bonferroni post hoc 
test), corresponding with prior observations (Chiu et al. 
2011). However, there were no statistically significant 
improvements found in either the spontaneous locomotor 
activity (HD-vehicle: 2099.8±1249.3 cm vs. HD-VD3: 
2111.2±449.0 cm, p>0.05 Bonferroni post hoc test) or the 
total number of rears (HD-vehicle: 27.0±25.1 vs. HD-VD3: 
34.7±15.8, p>0.05 Bonferroni post hoc test) of the mice 
supplemented with VD3 compared to untreated animals 
throughout the study (Fig. 1).
Rotarod tests
A trend towards a decreased performance on the 
rotarod became apparent in HD mice in accordance 
with, but earlier than the development of the decreased 
locomotion and exploration (as measured on week 11; 
WT-vehicle: 149.1±51.9 sec vs. HD-vehicle: 130.2±42.0 sec); 
however, this did not reach statistical significance in the 
analyses of variance at any timepoints thereafter (p>0.05 at 
each time point; Bonferroni post hoc test). No tendentious 
difference was detected between VD3-supplemented and 
vehicle-treated groups in either of the strains (p>0.05 at 
each time point; Bonferroni post hoc test).
Analysis of survival
VD3 treatment remarkably increased the median 
lifespan within the HD transgenic group supplemented 
with VD3 compared to the vehicle-treated HD group 
[HD-veh: 73 (67–94) days vs. HD-VD3: 101 (74–109) days], 
which was in accordance with a significant difference in 
the Kaplan-Meier survival analysis (p=0.048 Mantel-Cox log 
rank test; Fig. 2).
DISCUSSION
In this study, we investigated the effects of high-dose 
systemic VD3 supplementation on life expectancy and 
motor performance of N171-82Q transgenic HD mice. 
The analysis of survival found a statistically significant 
38% increase of the median lifespan of VD3-treated HD 
mice compared to vehicle-treated HD controls. This is a 
similar magnitude of effect on life expectancy as reported 
by prior studies on HD transgenic mice with certain 
potentially neuroprotective agents or combinations, such 
as valproate (31.4%) (Zadori et al. 2009), the combination 
of lithium and valproate (31%) (Chiu et al. 2011), the 
combination of remacemide and coenzyme Q10 (31.8% 
in R62 HD transgenic strain and 17% in N171-82Q strain) 
(Ferrante et al. 2002), and a kynurenic acid analogue 
(30.7%) (Zadori et al. 2011). Being the first in this field, 
the authors suggest the potential neuroprotective effect 
of VD3 in an HD model. This concept seems feasible based 
on the previously reported proposed protective actions 
of VD3 against oxidative injury and neuroinflammation, 
in part via inhibiting the synthesis of iNOS, though the 
contribution of VDR-linked neurotrophic effects as well as 
epigenetic modifications cannot be excluded. As regards 
the potential role of iNOS downregulation, although the 
role of iNOS-mediated oxidative injury has been implicated 
in the pathogenesis of a number of neurodegenerative 
disorders (Durzun et al. 2013, Chen et al. 2000, Ciesielska et 
al. 2003) and its activity has been found markedly increased 
in neurotoxin models of HD (Schmidt et al. 1995, Pérez-De 
La Cruz et al. 2005, Schulz et al. 1995, Milstien et al. 1994, 
DiCiero Miranda et al. 2000), its level has been consistently 
found unaltered or even slightly decreased in the striatum 
of transgenic HD mice by independent groups (Deckel et al. 
2001, 2002, Pérez-Severiano et al. 2002), leaving this issue 
open for further discussion.
In contrast with such a marked beneficial effect of VD3 
on survival, the treatment did not significantly improve 
the locomotor performance of HD mice in the open-field. 
Though by the time rotarod performance started to 
markedly decrease the serial occurrence of death events 
among transgenic animals resulted in a gradual loss 
of statistical power to show significant difference, the 
apparent trend to exert a decreased performance did 
not seem to be affected by VD3 treatment either. This 
conflict may arise from an impaired physiological profile 
of the skeletal muscle of N171-82Q mice exhibiting 
a decreased ability to form type-I (fatigue resistant) 
muscle fibers, most probably due to a diminished 
expression of peroxisome proliferator-activated 
receptor γ coactivator-1α (PGC-1α) protein, a key player 
in mitochondrial biogenesis and energy metabolism 
(Chaturvedi et al. 2009). Notably, agents providing 
similar improvement in survival but no overt effect on 
Fig. 2. The Kaplan-Meier survival curves of HD mice treated with VD3 and 
vehicle. A significant increase in the days of survival was shown in the 
VD3-treated group compared to the control HD mice [HD-vehicle: 73 (67–94) 
days vs. HD-VD3: 101 (74–109) days, p=0.048 Mantel-Cox log rank test].
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motor performance in HD transgenic mice has been 
described earlier in the literature (Gardian et al. 2005). 
Nevertheless, the findings that long-term high-dose 
VD3 treatment did not induce motor deficits in the mice 
confirms the safety of this therapy, with most probably 
no physiologically significant effect on serum calcium 
levels, similarly to that had been previously described 
in mice (Dusad et al. 2015). On interpreting the results, 
while it is tempting speculate a neuroprotective effect 
underlying the observed increase in survival, we could 
not exclude a general corroborative effect of VD3 
supplementation underlying this increase, especially in 
light of the reports of decreased VD3 serum levels in HD 
patients. Further investigations are needed to permit 
conclusions on this issue.
CONCLUSIONS
Long-term systemic VD3 supplementation lead to a 
remarkable increase in the survival of N171-82Q transgenic 
HD mice. This is in line with prior reports on beneficial 
effects of VD3 treatment in experimental models of other 
neurodegenerative diseases, as well as with the insufficient 
levels of VD3 in HD patients showing a negative correlation 
with disease severity. While further investigations are 
needed to determine whether neuroprotective or a general 
corroborative effect of VD3 leads to such an elongation of 
the lifespan of HD transgenic mice, the results supports 
the safety and the therapeutic potential of VD3 as a 
supplementary treatment for HD patients, especially for 
those with established VD3 deficiency.
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